Loading organizations...
§ Private Profile · Zürich, Zurich, Switzerland
Biotech company developing therapeutic antibody fragments for dermatological and inflammatory diseases using PENTRA® technology.
Delenex Therapeutics is a Schlieren, Swiss biotechnology company that develops therapeutic antibody fragments for dermatological and inflammatory diseases. The organization utilizes its proprietary PENTRA technology to create treatments designed for topical or local administration, targeting mild to moderate conditions like psoriasis and hidradenitis suppurativa. In 2014, the firm released clinical data for its TNF-targeting candidate DLX105, demonstrating biologic activity in psoriasis patients. Founded in September 2009 as a spinout from ESBATech, the enterprise secured multiple rounds of venture capital financing, including an initial 13,500,000 Swiss franc Series A round and a subsequent 7,300,000 Swiss franc Series A3 tranche. Led by executives like Chairman Thomas Hecht and Chief Scientific Officer Titus Kretzschmar, Delenex Therapeutics received financial backing from notable institutional investors such as SV Life Sciences and HBM BioCapital before being acquired by Cell Medica in July 2016.
Delenex Therapeutics has raised $41.2M across 3 funding rounds.
Delenex Therapeutics has raised $41.2M in total across 3 funding rounds.
Delenex Therapeutics has raised $41.2M across 3 funding rounds. Most recently, it raised $8.0M Series A Extension in November 2013.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 6, 2013 | $8M Series A Plus | — | BioMedPartners, HBM Partners, Novo Holdings, SV Health Investors, Venture Incubator | Announced |
| May 3, 2011 | $19.4M Series A Plus | Thomas Dyrberg | BioMedPartners, HBM Healthcare Investments, SV Health Investors, VI Partners | Announced |
| Nov 12, 2010 | $13.8M Series A | BioMedPartners, HBM Healthcare Investments, SV Health Investors, VI Partners | — | Announced |
Delenex Therapeutics has raised $41.2M in total across 3 funding rounds.
Delenex Therapeutics's investors include BioMedPartners, HBM Partners, Novo Holdings, SV Health Investors, Venture Incubator, Thomas Dyrberg, HBM Healthcare Investments, VI Partners.